- Home
- KPRX vs EKSO Comparison
KPRX vs EKSO Comparison
Compare KPRX & EKSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- EKSO
- Stock Information
- Founded
- KPRX 1998
- EKSO 2005
- Country
- KPRX United States
- EKSO United States
- Employees
- KPRX N/A
- EKSO N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EKSO Medical/Dental Instruments
- Sector
- KPRX Health Care
- EKSO Health Care
- Exchange
- KPRX Nasdaq
- EKSO Nasdaq
- Market Cap
- KPRX 8.6M
- EKSO 7.7M
- IPO Year
- KPRX N/A
- EKSO N/A
- Fundamental
- Price
- KPRX $2.99
- EKSO $4.82
- Analyst Decision
- KPRX Strong Buy
- EKSO Strong Buy
- Analyst Count
- KPRX 1
- EKSO 2
- Target Price
- KPRX $10.00
- EKSO $37.50
- AVG Volume (30 Days)
- KPRX 62.4K
- EKSO 105.4K
- Earning Date
- KPRX 08-08-2025
- EKSO 07-28-2025
- Dividend Yield
- KPRX N/A
- EKSO N/A
- EPS Growth
- KPRX N/A
- EKSO N/A
- EPS
- KPRX N/A
- EKSO N/A
- Revenue
- KPRX $20,000.00
- EKSO $17,544,000.00
- Revenue This Year
- KPRX N/A
- EKSO $0.20
- Revenue Next Year
- KPRX N/A
- EKSO $42.29
- P/E Ratio
- KPRX N/A
- EKSO N/A
- Revenue Growth
- KPRX N/A
- EKSO N/A
- 52 Week Low
- KPRX $2.51
- EKSO $2.73
- 52 Week High
- KPRX $4.80
- EKSO $22.95
- Technical
- Relative Strength Index (RSI)
- KPRX 47.28
- EKSO 69.09
- Support Level
- KPRX $2.96
- EKSO $3.79
- Resistance Level
- KPRX $3.29
- EKSO $4.28
- Average True Range (ATR)
- KPRX 0.15
- EKSO 0.35
- MACD
- KPRX 0.01
- EKSO 0.21
- Stochastic Oscillator
- KPRX 38.78
- EKSO 98.82
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.